Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Autologous stem cell transplantation beyond 60 years of age

Bone Marrow Transplantation volume 38, pages 715–720 (2006)Cite this article

Abstract

Along with improved supportive care and thus reduced treatment-related mortality, an increasing number of elderly patients (>60 years) with haematological malignancies are now considered for high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT). ASCT is feasible in selected elderly patients with multiple myeloma and those with non-Hodgkin's lymphoma. As elderly patients have generally been excluded from randomized studies evaluating efficacy of ASCT in comparison with non-transplant approaches, limited data are available on the efficacy of ASCT in this patient population. Recent developments in supportive care including amifostine and palifermin may increase feasibility of ASCT in elderly patients. Prospective studies are needed to evaluate feasibility and efficacy of ASCT in patients over 60 years of age. Also, further studies are needed in order to decrease toxicity of high-dose regimens in this patient group where co-morbid conditions may modify the toxicity of HDT in a clinically significant manner.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Clavio M, Casciaro S, Gati AM, Spriano L, Bonanni F, Poggi A et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica 1996; 81: 238–244.

    CAS  PubMed  Google Scholar 

  2. Riccardi A, Mora O, Brugnatelli S, Tinelli C, Spanedda R, de Paoli A et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Br J Cancer 1998; 77: 485–491.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Vose J, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–1844.

    Article  CAS  PubMed  Google Scholar 

  4. Bertini M, Boccomini C, Calvi R . The influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). Clin Lymphoma 2001; 1: 278–284.

    Article  CAS  PubMed  Google Scholar 

  5. Gratwohl A, Schmid O, Baldomero H, Horisberger B, Urbano-Ispizua A, for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indications and impact of team density. Bone Marrow Transplant 2004; 34: 855–875.

    Article  CAS  PubMed  Google Scholar 

  6. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours, and immune disorders: definitions and current policy in Europe. Bone Marrow Transplant 2006; 37: 439–449.

    Article  CAS  PubMed  Google Scholar 

  7. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Szer J . Haemopoietic stem cell transplantation in Australia and New Zealand, 1992–2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry. Intern Med J 2005; 35: 18–27.

    Article  CAS  PubMed  Google Scholar 

  8. Jantunen E, Itälä M, Lehtinen T, Kuittinen O, Koivunen E, Leppä S et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol 2006; 76: 245–250.

    Article  CAS  PubMed  Google Scholar 

  9. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472–2479.

    Article  CAS  PubMed  Google Scholar 

  10. Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H et al. Randomized study to evaluate the use of high-dose therapy as a part of primary treatment for ‘aggressive’ lymphoma. J Clin Oncol 2002; 20: 4413–4419.

    Article  CAS  PubMed  Google Scholar 

  11. Lenz G, Dreyling M, Schiegnitz E, Forstpoitner R, Wandt H, Freund M et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667–2674.

    Article  CAS  PubMed  Google Scholar 

  12. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Bethou C et al. Initial treatment pf aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295.

    Article  CAS  PubMed  Google Scholar 

  13. Geisler C, Elonen E, Kolstad A, Laurell A, Andersen NS, Pedersen L et al. Nordic Mantle Cell Lymphoma (MCL) Project: prolonged follow-up of 86 patients treated with BEAM/BEAC+PBSCT confirm that addition of high-dose AraC and rituximab to CHOP induction + in vivo purging with rituximab increases clinical and molecular response rates, pcr-negative grafts, failure-free, relapse-free and overall survival. Blood 2004; 104: 6a (abstract).

    Article  Google Scholar 

  14. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R et al. Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: results of a prospective randomised trial of the European MCL Network. Blood 2005; 105: 2677–2684.

    Article  CAS  PubMed  Google Scholar 

  15. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  16. Attal M, Harousseau JL, Facon T, Guilhot F, Douen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

    Article  CAS  PubMed  Google Scholar 

  17. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  18. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockwit AJ, Verhoef GE et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144–2151.

    Article  CAS  PubMed  Google Scholar 

  19. Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomised IFM 99-04 protocol. Blood 2006; 107: 397–403.

    Article  CAS  PubMed  Google Scholar 

  20. Mileshkin LR, Seymour JF, Wolf MM, Gates P, Januszewicz EH, Joyce P et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma 2005; 46: 1575–1579.

    Article  CAS  PubMed  Google Scholar 

  21. Mazza P, Palazzo G, Amurri B, Cervellara M, Manna N, Fellini G et al. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in elderly: an interim report. Bone Marrow Transplant 1999; 23: 1273–1278.

    Article  CAS  PubMed  Google Scholar 

  22. Leger CS, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsh L . Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000; 6: 204–210.

    Article  CAS  PubMed  Google Scholar 

  23. de la Rubia J, Saavedra S, Sanz GF, Martin G, Moscardo F, Martinez J et al. Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 21–25.

    Article  CAS  PubMed  Google Scholar 

  24. Olivieri A, Capelli D, Montanari M, Brunori M, Massidda D, Poloni A et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for haematological malignancies: a single centre experience. Bone Marrow Transplant 2001; 27: 1189–1195.

    Article  CAS  PubMed  Google Scholar 

  25. Villela L, Sureda A, Canals C, Sanz Jr MA, Martino R, Valcarcel D et al. Low transplant-related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. Haematologica 2003; 88: 300–305.

    PubMed  Google Scholar 

  26. Hertenstein B, Stefanic M, Schmeiser T, Scholz M, Goller V, Clausen M et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994; 12: 998–1004.

    Article  CAS  PubMed  Google Scholar 

  27. Lehmann S, Isberg B, Ljungman P, Paul C . Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26: 187–192.

    Article  CAS  PubMed  Google Scholar 

  28. Brockstein BE, Smiley C, Al-Sadir J, Williams SF . Cardiac and pulmonary toxicity in patients undergoing high-dose therapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 2000; 25: 885–894.

    Article  CAS  PubMed  Google Scholar 

  29. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

    CAS  PubMed  Google Scholar 

  30. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al., for the Nordic Myeloma Study Group. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000; 95: 7–11.

    CAS  PubMed  Google Scholar 

  31. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735.

    Article  CAS  PubMed  Google Scholar 

  32. Guba SC, Vesole DH, Jagannath S, Bracy D, Barlogie B, Tricot G . Peripheral stem cell mobilization and engraftment in patients over 60 years of age. Bone Marrow Transplant 1997; 20: 1–3.

    Article  CAS  PubMed  Google Scholar 

  33. Jantunen E, Putkonen M, Nousiainen T, Pelliniemi T-T, Mahlamäki E, Remes K . Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347–351.

    Article  CAS  PubMed  Google Scholar 

  34. Jantunen E, Kuittinen T, Penttilä K, Lehtonen P, Mahlamäki E, Nousiainen T . High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated within the same protocol. Bone Marrow Transplant 2006; 37: 917–922.

    Article  CAS  PubMed  Google Scholar 

  35. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.

    Article  CAS  PubMed  Google Scholar 

  36. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years. J Clin Oncol 2005; 23: 9227–9233.

    Article  CAS  PubMed  Google Scholar 

  37. Reece DE, Bredeson C, Perez WS, Jagannath S, Zhang MJ, Ballen KK et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age. Bone Marrow Transplant 2003; 32: 1135–1143.

    Article  CAS  PubMed  Google Scholar 

  38. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533–539.

    Article  CAS  PubMed  Google Scholar 

  39. Krejci M, Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L et al. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 2005; 35: 159–164.

    Article  CAS  PubMed  Google Scholar 

  40. Sirohi B, Powles R, Mehta J, Rudin C, Kulkarni S, Horton C et al. An elective single autograft with high-dose melphalan: single-center analysis of 451 patients. Bone Marrow Transplant 2005; 36: 19–24.

    Article  CAS  PubMed  Google Scholar 

  41. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54.

    CAS  PubMed  Google Scholar 

  42. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E et al. Autologous stem cell transplantation in multiple myeloma: improved survival in non-secretory myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single centre experience of 127 patients. Bone Marrow Transplant 2003; 31: 163–170.

    Article  CAS  PubMed  Google Scholar 

  43. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253.

    CAS  PubMed  Google Scholar 

  44. Samuels BL, Bitran JD . High-dose melphalan: a review. J Clin Oncol 1995; 13: 1786–1799.

    Article  CAS  PubMed  Google Scholar 

  45. Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective Italian multicenter study. J Clin Oncol 1996; 14: 534–542.

    Article  CAS  PubMed  Google Scholar 

  46. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective LNH 87-2. J Clin Oncol 1997; 15: 1131–1137.

    Article  CAS  PubMed  Google Scholar 

  47. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.

    Article  CAS  PubMed  Google Scholar 

  48. Verdonck LF, van Putten WLJ, Hagenbeek A, Schouten HC, Sonnevelt P, van Imhoff GW et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation in slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045–1051.

    Article  CAS  PubMed  Google Scholar 

  49. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordjik FM et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: a randomised phase III EORTC study. J Natl Cancer Inst 2001; 93: 22–30.

    Article  CAS  PubMed  Google Scholar 

  50. Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Contonetti M et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003; 21: 1255–1262.

    Article  PubMed  Google Scholar 

  51. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235–242.

    Article  CAS  PubMed  Google Scholar 

  52. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of DSHNHL. Blood 2004; 104: 634–641.

    Article  CAS  PubMed  Google Scholar 

  53. Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared to salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  54. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3894–3896.

    Article  Google Scholar 

  55. Russell NH, McQuaker G, Stainer C, Byrne JL, Haynes AP . Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998; 22: 935–940.

    Article  CAS  PubMed  Google Scholar 

  56. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–242.

    Article  CAS  PubMed  Google Scholar 

  57. Sugrue MW, Williams K, Pollock BH, Khan S, Peracha S, Wingard JR et al. Characterization and outcome of ‘hard to mobilise’ lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000; 39: 509–519.

    Article  CAS  PubMed  Google Scholar 

  58. Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E . Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907–912.

    Article  CAS  PubMed  Google Scholar 

  59. Jantunen E, Mahlamäki E, Nousiainen T . Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (&gt;60 years) with non-Hodgkin's lymphoma: comparison with patients &lt;60 years treated within the same protocol. Bone Marrow Transplant 2000; 26: 737–741.

    Article  CAS  PubMed  Google Scholar 

  60. Stamatoullas A, Fruchart C, Khalfallah S, Buchonnet G, Contentin N, Bastit D et al. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplant 1997; 19: 31–35.

    Article  CAS  PubMed  Google Scholar 

  61. Moreau P, Milpied N, Voillat L, Colombat P, Mahe B, Rapp MJ et al. Peripheral blood stem cell transplantation as front line therapy in patients aged 61–65 years: a pilot study. Bone Marrow Transplant 1998; 21: 1193–1196.

    Article  CAS  PubMed  Google Scholar 

  62. Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adult 60 years of age and older. Bone Marrow Transplant 2001; 27: 593–599.

    Article  CAS  PubMed  Google Scholar 

  63. Zallio F, Cuttica A, Caracciolo D, Gavarotti P, Bergui L, Giaretta F et al. Feasibility of peripheral blood progenitor cell mobilisation and harvest to support chemotherapy intensification in elderly patients with poor prognosis non-Hodgkin's lymphoma. Ann Hematol 2002; 81: 448–453.

    Article  CAS  PubMed  Google Scholar 

  64. Bitran JD, Klein L, Link D, Kosirog-Glowacki J, Stewart C, Raack D et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation in elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003; 9: 383–388.

    Article  PubMed  Google Scholar 

  65. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliott MA et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 37: 1017–1022.

    Article  CAS  PubMed  Google Scholar 

  66. Jantunen E, Itälä M, Juvonen E, Leppä S, Keskinen L, Vasala K et al. Autologous stem cell transplantation in elderly (&gt;60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006; 37: 367–372.

    Article  CAS  PubMed  Google Scholar 

  67. Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Amaud P et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 769–775.

    Article  CAS  PubMed  Google Scholar 

  68. Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005; 35: 971–977.

    Article  CAS  PubMed  Google Scholar 

  69. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Kuopio University Hospital, Kuopio, Finland

    E Jantunen

Authors
  1. E Jantunen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Jantunen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jantunen, E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant 38, 715–720 (2006). https://doi.org/10.1038/sj.bmt.1705514

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705514

Keywords

This article is cited by

Search

Advanced search

Quick links